KEY DETAILS
A new Phase 3 trial called SYNCHRONIZE-HERA will test whether survodutide helps women with obesity lose weight during or after menopause.
A separate Phase 3 trial, ELEVATE-LIVER, will enroll 600 people to see if survodutide improves heart structure and function in those with obesity and fatty liver disease.
Two new Phase 3 trials for survodutide, a GLP-1-like drug, were posted on Thursday, October 1, 2026. Together they test the drug in two different patient groups: women managing weight during or after menopause, and people with obesity and fatty liver disease. If you fall into either group, these trials may offer an early look at where GLP-1 treatment options are heading next. Neither trial is recruiting yet, but both are worth watching.
The SYNCHRONIZE-HERA trial is built around a question that general weight loss studies tend to skip over: whether a GLP-1-like drug works the same way for women during or after menopause as it does for other patients. Hormonal changes during this stage of life can affect how the body gains and holds onto weight, so testing survodutide specifically in this group is a meaningful departure from the usual trial design. The study has not opened for recruitment yet, so there is no enrollment information to act on right now. Still, if you are managing weight during or after menopause, this is a trial worth tracking as it moves toward recruitment, since it may eventually offer a treatment option designed with your situation in mind.
The ELEVATE-LIVER trial takes a different angle, enrolling 600 people with obesity and fatty liver disease to see whether survodutide improves heart structure and function. Pairing liver disease with heart outcomes in one study reflects how closely these conditions are linked in patients with obesity, and it suggests researchers want data on more than weight loss alone. A trial of this size, at 600 participants, is substantial enough to produce findings that could shape how survodutide is positioned if it reaches the market. As with the menopause trial, recruitment has not started, so there is nothing to sign up for yet. People living with obesity and fatty liver disease may want to keep an eye on this one, particularly if heart health is also a concern.
Neither trial is open for enrollment yet, so there is no action to take today beyond staying informed. I would suggest bookmarking both studies if either one applies to your situation, so you can check back as they move toward recruitment. It may also help to mention these trials to your doctor at your next visit, especially if you are weighing GLP-1 options for menopause-related weight changes or for fatty liver disease. These two trials are an early signal that GLP-1 competition is expanding past diabetes and general weight loss, but the decision about whether either path fits your care is one to make with your own medical team.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.